title: Risk of preeclampsia in HIV-positive pregnant women receiving HAART: a matched cohort study.
abstract: OBJECTIVE
  We sought to determine whether HIV-positive women receiving highly active anti-retroviral therapy (HAART) are at higher risk for preeclampsia than HIV-negative women. Secondary outcomes included comparing the risks of preterm birth, low birth weight, and small for gestational age birth in these women.
  
  
  METHODS
  In this retrospective matched cohort study, we compared the pregnancy outcomes of HIV-positive women treated with HAART with those of HIV-negative women who gave birth at Mount Sinai Hospital, Toronto, Ontario. Data were ascertained through chart review. Univariate and multivariate logistic regression models were used to compare pregnancy outcomes between the two groups.
  
  
  RESULTS
  Ninety-one HIV-positive pregnant women receiving HAART and 273 HIV-negative pregnant women were identified. After adjusting for confounding factors, there was no difference between HIV-positive and HIV-negative women in the odds of preeclampsia (3.3% vs. 5.1%; adjusted odds ratio [aOR] 0.59; 95% CI  0.11 to 3.08), preterm birth (15.6% vs. 11.4%; aOR 1.70, 95% CI 0.79 to 3.66) or small for gestational age infants (20.2% vs. 8.8%; aOR 2.08, 95% CI 0.89 to 5.24). HIV-positive women treated with HAART had increased odds of giving birth to a low birth weight infant compared to HIV-negative women (20.2% vs. 9.9%; aOR 2.91; 95% CI 1.47 to 5.78).
  
  
  CONCLUSIONS
  In this cohort, HIV-positive women on HAART did not demonstrate a higher risk of preeclampsia, preterm birth, or small for gestational age infants; however, they did have a higher risk of having low birth weight infants.
authors.affiliation: Faculty of Medicine, University of Toronto, Toronto ON; Department of Health Policy, Management and Evaluation, University of Toronto, Toronto ON.
authors.forename: Talar
authors.initials: T
authors.lastname: Boyajian
authors.affiliation: Department of Health Policy, Management and Evaluation, University of Toronto, Toronto ON; Department of Pediatrics, Mt. Sinai Hospital, Toronto ON; Division of Neonatology, Department of Pediatrics, University of Toronto, Toronto ON.
authors.forename: Prakesh S
authors.initials: PS
authors.lastname: Shah
authors.affiliation: Department of Health Policy, Management and Evaluation, University of Toronto, Toronto ON; Department of Obstetrics and Gynecology, Mount Sinai Hospital, Toronto ON; Department of Obstetrics and Gynecology, University of Toronto, Toronto ON.
authors.forename: Kellie E
authors.initials: KE
authors.lastname: Murphy
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D015331:Cohort Studies; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy*; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age; D016015:Logistic Models; D011225:Pre-Eclampsia / Q000453:epidemiology*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D047928:Premature Birth; D012189:Retrospective Studies; D012307:Risk Factors